Tag: Biotronik

Biotronik announces positive data for Magmaris

A press release from Biotronik highlights data from the BIOSOLVE-IV registry outlining procedural success and a positive safety profile at one year for its...

Biotronik launches PK Papyrus covered coronary stent in the USA

Biotronik has launched the PK Papyrus covered coronary stent system in the United States for use in the emergency treatment of acute coronary perforations....

CRT 2019: Early resorption and low complications demonstrated for Magmaris

A press release reports that preliminary data from the BIOSOLVE-IV registry strengthen the clinical evidence in favour a bioresorbable magnesium scaffold (Magmaris, Biotronik) for...

CRT 2019: Three-year data shows trend towards lower target vessel failure...

Three-year outcome data from the BIO-RESORT randomised controlled trial, which were presented at the 2019 Cardiovascular Research Technologies (CRT) meeting (2–5 March, Washington, DC,...

New Australian research and development partnership aims to innovate heart failure...

Biotronik, the University of Newcastle (in Australia), and the John Hunter New England Local Health District have partnered to shape a future heart failure...

FDA approves Orsiro for use in the USA

  The US FDA have approved Biotronik’s drug-eluting stent Orsiro. A press release states that Orsiro is the first and only ultrathin drug-eluting stent to...

Registry data for Biotronik’s bioresorbable scaffold Magmaris supports its roll-out into...

Preliminary data from the BIOSOLIVE-IV registry are consistent with the favourable safety outcomes seen with the magnesium bioresorbable scaffold (Magmaris, Biotronik) in previous studies...

TCT 2018: Orsiro continues to have lower rates of target lesion...

Two-year data from the BIOFLOW-V randomised trial—which compared a sirolimus stent with a biodegradable polymer (Orsiro, Biotronik) with a everoliums-eluting stent with a permanent...

US FDA approves PK Papyrus stent for coronary perforations

The US FDA has approved the PK Papyrus covered coronary stent system (Biotronik) under Humanitarian Device Exemption for use in the emergency treatment of...

ESC 2018: Higher all-cause mortality with Orsiro at five years than...

According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biodegradable polymer (Orsiro, Biotronik) have a similar overall safety and efficacy...

EuroPCR 2018: One- to two-year landmark analysis shows significantly lower target...

Two-year outcome data from the BIO-RESORT randomised controlled trial, which were presented in a late-breaking clinical trials session by Marlies M Kok (Thoraxcentrum Twente,...

EuroPCR 2018: Further evidence for safety and efficacy of Magmaris bioresorbable...

Data presented during EuroPCR (22 May – 25 May, Paris, France) provide further evidence on its continued safety and efficacy, also in a more complex...

CIT 2018: BIOFLOW-VI confirms non-inferiority of Orsiro to Xience

Nine and 12-month data for Orsiro—presented by Yang Yue Jin (Fu-Wai Hospital, National Center of Cardiovascular Disease, Beijing, China) at the China Interventional Therapeutics...

Japanese Ministry of Health approve Biotronik’s Orsiro drug-eluting stent

According to a Biotronik press release, the Japanese Ministry of Health has approved the company’s Orsiro coronary stent—a sirolimus-eluting stent with a biodegradable polymer—for...

TCT 2017: Pooled analysis of Magmaris studies continue to show no...

Data presented during the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA), according to a press release, provide further evidence of...

Enrolment in BIOVITESSE trial of polymer-free coronary stent initiated

Biotronik has announced the start of enrolment in a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary...

ESC 2017: Significantly lower event rates with Orsiro than with Xience

  Results from the BIOFLOW V study indicate that patients who undergo percutaneous coronary intervention (PCI) using a sirolimus-eluting stent with a biodegradable polymer (Orsiro,...

EuroPCR 2017: Low risk of scaffold thrombosis with Magmaris

Data presented at EuroPCR (16–19 May, Paris, France) indicate that a metallic bioresorbable scaffold (Biotronik) is associated with a lower risk of scaffold thrombosis...

Magnesium 1,000 programme reveals high deployment success for Biotronik’s Magmaris scaffold

Biotronik has released details of the clinical performance of its Magmaris magnesium scaffold in 1,000 cases as part of the Magnesium 1,000 programme. Among...

BIOFLOW-IV confirms non-inferiority of Biotronik’s Orsiro in Japan

The 12-month results of Biotronik’s BIOFLOW-IV multicentre clinical study have been presented at the 2-17 Japan Circulation Society congress (JCS; 17-19 March, Kanazawa, Japan)....

FDA approves Biotronik’s Pro-Kinetic Energy bare metal stent

Biotronik’s Pro-Kinetic Energy bare metal stent has received FDA approval, which is based on the results of the BIOHELIX-I clinical study. Therefore, the stent, which...

TCT 2016: Physicians discuss their positive experiences of using a metallic...

At a symposium at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA), physicians discussed their first experiences with a...